Pankreaskarzinom: Schlüssige klinische Konsequenzen aus molekularbiologischen Kenntnissen für die Therapie.

Molecular research techniques developed in recent years have increased our knowledge of the pathophysiology of pancreatic cancer tremendously. We now know that the malignant phenotype of pancreatic cancer is defined by the expression of growth stimulatory factors, their receptors and gene alterations. To translate molecular knowledge into new clinical therapy will be the challenge of the future. Although we have not yet developed direct clinical applications for our molecular findings, new diagnostic and therapeutic approaches are in development. Gene therapies such as antisense technology, pro-drug activation and the transfer of non-functioning growth factor receptors are potential new therapeutic options for the future. Wider clinical use can be expected in upcoming years.